指南与共识医院感染防控病毒性肝炎细菌感染、耐药与抗菌药物

ESCMID 免疫功能受损宿主感染研究组(ESGICH)关于靶向与生物治疗安全性的共识文件:感染病学视角(靶向淋巴细胞表面抗原的药物[I]:CD19、CD20 与 CD52)

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52).
指南 / 共识 · Clin Microbiol Infect · 2018-02-12

该共识由 ESCMID 免疫功能受损宿主感染研究组制定,基于 MEDLINE 检索综述靶向 CD19、CD20 和 CD52 药物的感染安全性。CD19 靶向药不增加感染风险但可致 IgG 低丙种球蛋白血症和中性粒细胞减少;抗 CD20 单抗感染常见,需筛查 HBV 并预防性抗病毒 12–18 个月;阿仑单抗增加感染风险,需预防肺孢子菌、巨细胞病毒及筛查 HBV、HCV 和结核。

要点

  • CD19 靶向药不增加感染风险,但可致 IgG 低丙种球蛋白血症和中性粒细胞减少。
  • 接受抗 CD20 单抗者推荐筛查慢性或已缓解的 HBV 感染。
  • HBsAg 阳性及 HBsAg 阴性/抗 HBc 阳性者应给予 12–18 个月抗病毒预防。

核心结论

  • 许多被综述药物的临床数据有限,必须特别关注及时检测和报告新出现的感染性并发症。

研究设计与样本

  • ESCMID 免疫功能受损宿主感染研究组(ESGICH)共识文件,采用计算机 MEDLINE 检索,检索词涉及每种药物或治疗家族。

主要发现

  • CD19 靶向药物(贝林妥欧单抗或 inebilizumab)不增加感染风险,但可能引起 IgG 低丙种球蛋白血症和中性粒细胞减少。
  • 贝林妥欧单抗需长时间静脉输注,可能增加导管相关血流感染风险。
  • 感染仍是抗 CD20 单克隆抗体最常见的非血液学不良反应,包括严重呼吸道感染、乙型肝炎病毒(HBV)再激活和水痘-带状疱疹病毒感染。
  • 阿仑单抗(抗 CD52)增加感染风险,尤其在白血病和实体器官移植患者中。

关键数值与推荐

  • 接受抗 CD20 单克隆抗体者推荐筛查慢性或已缓解的 HBV 感染。
  • HBsAg 阳性和 HBsAg 阴性/抗 HBc 阳性者应给予 12–18 个月抗病毒预防。
  • 接受联合化疗(尤其糖皮质激素)者应考虑肺孢子菌预防。
  • 白血病和实体器官移植患者可从肺孢子菌预防、巨细胞病毒感染预防策略及 HBV、丙型肝炎病毒和结核筛查中获益。
  • HBsAg 阳性者应给予至少 6–12 个月抗病毒预防。

临床怎么用

  • 接受抗 CD20 单克隆抗体者推荐筛查慢性或已缓解的 HBV 感染,HBsAg 阳性及 HBsAg 阴性/抗 HBc 阳性者应给予 12–18 个月抗病毒预防。
  • 接受联合化疗(尤其糖皮质激素)者应考虑肺孢子菌预防。
  • 白血病和实体器官移植患者可从肺孢子菌预防、巨细胞病毒感染预防策略及 HBV、丙型肝炎病毒和结核筛查中获益。
  • HBsAg 阳性者应给予至少 6–12 个月抗病毒预防。

局限性

  • 许多被综述药物的临床数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The present review is part of the ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies. AIMS: To review, from an Infectious Diseases perspective, the safety profile of agents targeting CD19, CD20 and CD52 and to suggest preventive recommendations. SOURCES: Computer-based MEDLINE searches with MeSH terms pertaining to each agent or therapeutic family. CONTENT: Although CD19-targeted agents (blinatumomab or inebilizumab) are not associated with an increased risk of infection, they may cause IgG hypogammaglobulinaemia and neutropenia. The requirement for prolonged intravenous infusion of blinatumomab may increase the risk of catheter-associated bloodstream infections. Infection remains the most common non-haematological adverse effect of anti-CD20 monoclonal antibodies, including severe respiratory tract infection, hepatitis B virus (HBV) reactivation and varicella-zoster virus infection. Screening for chronic or resolved HBV infection is recommended for patients receiving anti-CD20 monoclonal antibodies. Antiviral prophylaxis should be offered for 12-18 months to hepatitis B surface antigen (HBsAg)-positive and HBsAg-negative/anti-hepatitis B core antibody (HBc)-positive patients. Anti-Pneumocystis prophylaxis should be considered in patients receiving concomitant chemotherapy, particularly steroids. Alemtuzumab (anti-CD52) increases the risk of infections, in particular among leukaemia and solid organ transplant patients. These populations benefit from anti-Pneumocystis prophylaxis, prevention strategies for cytomegalovirus infection, and screening for HBV, hepatitis C virus and tuberculosis. Antiviral prophylaxis for at least 6-12 months should be provided for HBsAg-positive patients. IMPLICATIONS: As there are limited clinical data for many of the reviewed agents, special attention must be given to promptly detect and report emerging infectious complications.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Mikulska M, Lanini S, Gudiol C, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52). Clin Microbiol Infect. 2018. PMID: 29447988. doi:10.1016/j.cmi.2018.02.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。